IDE

Spoonyyy

Totally get this. I'm a security engineer and I've been leveraging an AI-assisted IDE and it's definitely accelerated my development time. I've had to do some back and forth, but overall not as much as me having to work with an engineering team that has me do the same type of requirement, design, etc,.

SweatyMammal

There’s so many variables to the effectiveness of using AI for coding at the moment. Variables like: Which model are you using? What prompts are you using? Is it an existing codebase? Which IDE are you using? Are you using the ‘plan’ modes at one step and the ‘agent’ modes for the implementation? To get good results is definitely learning curve, and devs are hesitant to try using tools that can replace their jobs. It doesn’t help that everything gets lumped into a general ‘AI‘ bucket, which isn’t very useful when models can vary wildly in performance. I’m not surprised we’re not seeing huge upswings yet because it seems we’re still in that learning and experimentation phase as devs start to integrate it into their workflows. For new tools I wouldn’t think twice about using AI to create those. I’ve had good amounts of success with getting whole new tools set up in a couple hours or so.

soldier_18

Google has an entire ecosystem and they have been really smart on how they are integrating Gemini in an impressive velocity and google also owns around 14% of **Anthropic** (Claude) so thats interesting because Claude still remains in general as the best AI for coding, so its like the best of both worlds and with the new Antigravity IDE, google is killing it. Here is where you can see how Microsoft is getting so far behind, because they also have a massige ecosystem with OneDrive, Excel, PPT, Word, windows and Copilot is not even close to Gemini, Claude or Chatgpt. Anyways, I see Google achieving the dominance because of their capability to offer other stuff along with Gemini, they are being smart on attracting new clients or having other to upgrade their current plan, for example they give you 2TB storage with your PRO subscription (20$), again Microsoft can offer something similar but they are like sleeping in the water. And remember, Google was like 2 years behind all of them, really impresive.

foo-bar-nlogn-100

But it's just making AI slop. Like, how has it made anyone money other than NVDA. Every company I hear is losing money. I hear Cursor IDE is losing money now because of people migrating to Antigravity and Gemini. I am a bot.

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting Including ‏FDA PHASE 3 completion for one indication in H1 2026 ‏And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy… and of course Japan where they are expected approval) ‏Patents, IP and more…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting Including ‏FDA PHASE 3 completion for one indication in H1 2026 ‏And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy… and of course Japan where they are expected approval) ‏Patents, IP and more…

Pristine_Hurry_4693

Keytruda is the #1 selling drug worldwide, all that despite only 19% of patients responding and only 5% showing complete response. Although a small sample size, but a combination therapy trial using Keytruda with a DRTS treatment (which has shown the ability to activate the immune system) has shown effectively 100% patient response and 50% complete response. If this holds up it’s an industry changer in and of itself, so the this is what they are potentially looking into with a larger trial and an FDA IDE to do so

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for five cancers and counting Including ‏FDA PHASE 3 completion for one indication in H1 2026 ‏And FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system ⁠50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

CryptoThroway8205

I don't think many people are using self hosted deepseek as their model in their IDE to write code. In order to catch up you still need to train and even if the cost of chips crashes the cost of electricity and water won't. The difference between 80% accuracy and 85% is massive because of perception and companies are likely going to be the ones paying for the 85%. I think we're going to see free models better than self hosted deepseek disappear since they won't be able to keep running at cost to gain market share.

Pristine_Hurry_4693

Agree to disagree. First of all, sadly, there are enough cancer cases for many companies to be successful (please god let’s get to the day that a company could have a cancer treatment but the competition for good treatments outweighs the need for them) Secondly, DRTS is in phase 3 of the FDA with five IDE’s going on, expecting PMDA approval any day now, have all the cash on hand etc etc, the risk is almost nonexistent while the reward could be anywhere between 10-100+ per share (with 10 coming in the next quarter and 100+ coming after)

Pristine_Hurry_4693

Happy to hear you read about it, that’s the real point of the post (always DYOR, although I do believe it’s a good buy) Of course it’s NFA, and I understand the hesitancy and would never tell anyone if or when to buy, I would just note that it was sitting around 4$ and has then risen off of real good news (specifically the GBM, but that’s after the Pancreas as well, getting FDA approval for the manufacturing facility, getting an IDE for Prostate and more and more), so even if the price corrects a little, there’s no reason it shouldn’t stay around these levels (with the PMDA around the corner, not knowing when it really gets announced and then it probably has a run) I’ve been following the company for years now, accumulating along the way so my average is lower than the current price, but I ain’t selling anytime soon I’m long and truly believe in the potential

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Pristine_Hurry_4693

It’s a process, the treatment itself has proven to be effective 100% of the time (meaning there has yet to be a solid tumor that hasn’t responded, it’s basically physics). Now the “challenge” is to get access to the tumors in a safe way, to implement the treatment, which slowly (and ramping up quickly) has happened tumor type after tumor type. The company gets an approval to treat -> successfully treats (proving both safety and effectiveness) -> gets approval for larger scale trials -> success again -> and so on and so forth. They have 5 simultaneous IDE’s with one of them being phase 3 of the FDA, and that’s only in the US as they are treating in many other countries as well

Pristine_Hurry_4693

DRTS has many catalysts lined up: Yesterday successfully treated 1st GBM patient (IDE will continue and results will come) PMDA approval in Japan (near term, could be as soon as before EOY) Pancreas study progress and results (first patient was successfully treated) Phase 3 recruitment completion for cSCC New FDA trials launching (most recently prostate while next could be head & neck) Commercial manufacturing facility completion (recently approved by the FDA)

Pristine_Hurry_4693

They recently completed a 30-40 Pancreatic Cancer patients trial in Canada, they have 5 IDE’s going on with the cSCC being phase 3, and have 50+ clinical sites worldwide along with many years of preclinical treatments and data. The actual treatment is pretty much physics as you could see here: https://youtu.be/rLgMmDbJxJ8?si=3IiRl3pZ5v_OGHKW And there are patient testimonials there as well: https://youtu.be/3-wKoSCozA8?si=ZwTHE2JlrPTUadmY

Pristine_Hurry_4693

Great points! First note is that the treatment activates the immune system as well, since the treatment doesn’t harm the healthy tissue around the tumor it allows the body to learn to detect the cancer cells and how to attack them. To address the funnel, they could pretty much treat all shapes and sizes, but more importantly (to answer the business concerns) this treatment is effective for ALL solid tumors. Skin, head and neck, pancreas, lungs, breast, prostate and more have all been treated successfully in pre clinical and some already in clinical (they have five IDE’s live in the US), so the patient population (sadly) is millions of annually new cases. And lastly to the point about other countries, they already have clinical sites in the UK, Germany, Italy, France, Russia, Canada and more…

Pristine_Hurry_4693

First of all I’m 100% with you on the beat cancer front, that’s what’s really exciting about it (it just happens to be that if it is successful at saving millions of people it will then make investors millions of dollars). And on the FDA front, the FDA loves DRTS. They just granted them their FIFTH simultaneous IDE. They awarded them with Breakthrough Device Designation. Accepted them into the TAP program. Certified them with the MDSAP. And more…

Pristine_Hurry_4693

The ceiling is really high, the treatment is effective for all solid tumors, with dozens successfully tested in pre clinical trials (yet to find a tumor that doesn’t respond, including breast, lungs, pancreas, prostate, skin, head and neck etc) and 5(!) currently active IDE’s If we take just pancreas for example, and only in the US, that’s 60K new annual cases that would need the DRTS treatment, with a cost basis of say 100K$ that’s billions in annual revenue from one indication alone and only in the US. With a market cap of only ~350M… price target could be 10$+ easily (in the near term say a few months from now)

ImaginationBroad2590

They’re both early so it’s hard to directly compare without more data. I prefer the alpha radiation approach from DRTS, I think it will prove to be highly destructive to tumor cells without being impacted by the tumor’s micro environment and with no impact to surrounding healthy tissue. As an investor, taking the IDE pathway to approval versus the IND pathway is also a significant difference, although PSTV is well ahead in the development process for GBM…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Next_Discipline_2808

Here’s the news about the fifth IDE: https://www.alphatau.com/single-post/alpha-tau-receives-fda-approval-to-initiate-a-trial-for-patients-with-locally-recurrent-prostate-can

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Pristine_Hurry_4693

Some seem to think that the GBM news could be a wake up call as well, and I could understand why. I don’t think the market is aware or understands that DRTS’s treatment could actually treat GBM, if that proves to be right (which it did in the earlier trials earning it the FDA Breakthrough Device Designation along with getting included in the FDA’s TAP program, and is now recruiting patients for the IDE) that could definitely get some attention as well.

Pristine_Hurry_4693

Spot on, there’s so much to love about it. Ppl treat the many IDE’s as if they are ‘many shots on goal’, although that might be true, and as none of them have been completed yet that might be of comfort for those afraid it might not get approved, but the truth of the matter is what you’ve said - it’s THE SAME treatment for all solid tumors, it’s just about proving they could reach and treat in a safe way. Each of the trials just further validates the treatment as it’s basic physics and works the same for all solid tumors, therefore increasing the TAM, which in DRTS’s case means more potential lives saved which is awesome to be a part of while enjoying the gains as well.

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

Pristine_Hurry_4693

**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** ‏FDA Breakthrough Device Designation ‏FDA TAP program inclusion ‏FDA MDSAP certification ‏FDA IDE’s for **five** cancers and counting ‏**FDA PHASE 3** completion for one indication in H1 2026 ‏FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) ‏FDA approval for commercial factory in the US, with other factories built and more in planing ⁠100% tumor response rate in early FDA trials ‏Effective against all tumor types, including unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… ‏Activates immune system response ⁠**50+ clinical sites worldwide** (including USA, UK, Canada, France, Germany, Russia, Italy…) ‏Patents, IP and more…

howtotailslide

They are paying cursor who does not have an AI model, it’s just an IDE that connects to existing models. Cursor is probably making money because they are not actually an AI company really, they are a customer. The existing AI models cost a shitload of energy and hardware to run, those companies are all hemorrhaging money like crazy lol

_hiddenscout

Not too much with the CLI tools. I work in test automation and do a lo more of the dev ops and what not for our pipelines on top of the test automation. Getting copilot into IDE has been great. Thing basically write code for you, but it only really works well if you have a foundation in code. Like to me, I think the days of being a JR developer is going to be way harder as companies just want to hire more experienced developers who work faster. I still think on the SaaS side of the world, you get more bottle necks from product. Like not getting good Acceptance Criteria on stories or bad designs. Being able to code faster is great, but doesn't mean you are going to ship faster, especially the larger the companies. The vibe coding stuff is cool. Kind of reminds me of like ruby on rails came out. Ruby on rails made it super easy to use a CLI and create everything you need for a web app. I just don't see a world, at least in bigger companies, where these tools are going to be more than productivity boosters. I do wonder if companies take a spin of building their own software first though.

EH_Story

The increase in screen understanding for Gemini 3 is such a massive game-changer for me and I don't believe the market has caught on yet. Antigravity is great as well, but screen-understanding has the potential to take agentic AI out of the IDE. This means potentially unlocking productivity benefits in back office functions outside of technology where the gains have so far been focused.

Clear_Anything1232

OpenAI is going to be ultra fucked by Googl The new model feedback is the exact opposite of how gpt 5 was received Apparently, they are crushing real world results and benchmarks Their new IDE has been tried by so many people that it crashed their login servers briefly I'm curious who will be dumb enough to throw money at openai in the next round

ectoblob

Yeah, Gemini 3 is also listed on Google's new IDE, 'Antigravity' page.

Pristine_Hurry_4693

I appreciate the genuine questions! Since it is a biotech stock, I believe the clinical trials failing, not getting FDA approval, running out of cash, and a general market crash are the biggest risks. I know I’m not necessarily supposed to counter, but for me a big part of the appeal of the stock is the risk management. The trials still might fail and there’s no way to know if and when the FDA will approve, but the results up to this day are amazing, and understanding how it works it’s basically physics that have been proven to work hundreds of time on dozens of tumors (every tumor tested has responded). The FDA has granted the treatment FDA breakthrough device designation, has accepted it into the FDA TAP program, it’s got MDSAP certification, FDA IDE’s for different cancer types, FDA approved its manufacturing facility and more so safe to say things are going well and the relationship with the FDA is a positive one. From the financial side they have runway for a few years, while the PMDA in Japan is expected to approve them to go to market very soon, and the FDA could as well for skin cancer (although their real goal is the inner organs) which could both mean it will no longer be pre-revenue.

ProudPeak3570

A fucking IDE is valued at 30B. This will collapse spectacularly

the__storm

Y Combinator just funded a startup building the "Chad IDE," which is an AI coding product that integrates brainrot activities directly into the interface while you wait for the LLM to generate your code. https://x.com/ycombinator/status/1988366241460089118 Too bad YC is private or I'd be all in, but at least we can dump some more money into NVDA.

JohanWuhan

Yes definitely. I’m using Juni in my IDE (Jetbrains IntelliJ). I think since Juni came out I can ship 5 times more features and it’s doing an amazing job. So let’s say, you have a backend which returns a list with users, and you want a react component to display those users. You can just tell Juni: “create a table component to display the users. Also add edit and delete buttons which should open modals”. That’s it. You can get some coffee and it will create it all for you. It analyses your codebase so all the code it’s generating will be in the same style. It’s like having multiple really good junior developers working for you. Is it perfect? No it’s not and you always have to check what it has done, but it saves me a lot of time.

Major_Complex5950

First of all The SI only 10%? And Its just getting approved for IDE (Investigational Device Exemption) and it will take atleast 2 years for the final PMA approval.

Major_Complex5950

The SI only 10%, And Its just getting approved for IDE (Investigational Device Exemption) and it will take atleast 2 years for the final PMA approval.

ireadfaces

PS: I am not bad mouthing the company. These are some of my observations, and I wanted honest opinions on what others know. So please take it as a discussion where I want to educate myself, rather than an attack on the company's future. I feel these numbers are barely moving. For a company that has been out for this long, at least that much growth is valid. Also, they are not pulling much (AWS revenue is 30+ billion) and Google cloud is at a third spot since inception. And their bread and butter, the search ads: You can yourself see that a lot of queries people used to make now go straight to ChatGPT (coding related queries to Claude or their GPT Powered IDE like Cursor). If these queries were still being funneled to gemini, it would have been a different ballgame, but given this data, I worry about the upcoming future unless they hit another killer product like Android.

ClideLennon

I remember the advent of Intellisense and how it mean not needing to look up method names in the docs anymore. That was a nice performance boost. I use Cursor with Claude 4 sonnet 4.5 as my daily IDE. I hit the tab key a bit more than when I was using copilot. It knows what I have in the clipboard and suggests that a lot. That's great. It's not doing any 5x or even 2x. It's just a nice tool. And it's all stuff I already knew how to do.

lax20attack

It really will! While it won't replace developers anytime soon, it's a great tool to use. It reminds me of the jump when IDE's started giving code auto complete suggestions. This is the next level to that.

MagicWishMonkey

I do dev work and I agree that agentic IDE's are the future, but it's not replacing anyone anytime soon. It's not a fun time to be on the job market, especially not if you're just starting your career. I use claude code on a daily basis and I'm in the process of rolling these tools out to my devs so I'm fairly familiar with them. I think what's happening right now is a confluence of factors where AI is just one dimension, it's a perfect storm of of economic uncertainty thanks to the idiots in the white house, uncertainty of how what the long term impact of AI will be, organizations cutting tech headcount because of the change to R&D accounting rules (which have recently been rolled back but it'll take time for orgs to adjust), and the glut of tech workers that have been flooding the market over the last decade or so because "everyone should learn how to code and make a million dollars".

lebroski_

No offense but IDE plug-ins used by code monkeys are only one use case. Some of us are software developers in the ai space making ai powered apps and it is taking us over a new threshold that wasnt possible even 2 years ago.

Playful-Voice-6250

1. Acoustic Science Division • Technologies like ADIO,WiSA,Sumerian , these are audio/wireless/acoustic-signal technologies • Use cases: triggering mobile devices via inaudible tones in ads, enabling audio-based consumer interactions, loyalty or rewards driven by audio cues.  2. Data Science & Data Monetization / Web 3.0 Platform • Products called DataScore, DataValue,Data Vault Bank — these are AI agents or engines that help enterprises assess the value / risk / quality of data, convert enterprise data into “structured, tradable assets,” price data, ensure regulatory compliance, etc.  • Information Data Exchange (IDE) / “Digital Twins” / licensing of name, image, likeness (NIL) / attaching metadata & immutable (blockchain) objects to real-world things.  3. Acquisitions & Licensing • Acquired CompuSystems, Inc. (CSI) assets (these are assets in event registration, data analytics, lead management for events, trade shows etc.). DVLT expects those to contribute to revenue and event-based customers.  • Licensing agreements, e.g. with NYIAX for ADIO (audio / advertising engagement), with GFT Rewards for using ADIO in mobile rewards/loyalty programs.  4. Partnerships • With IBM WatsoNx (watsonx.ai) to power DataScore, DataValue etc., to help with AI governance, compliance, infrastructure for data valuation.  • With CLEAR (for identity / KYC), to ensure identity verification in monetization / data exchange.  • Burke Products (defense / aerospace contracting partner) appears in their network. 

Pristine_Hurry_4693

Many are wary of Biotech, but just as all stocks it just needs the right research and situation. In short, DRTS is a life saving treatment, the company has the financial runway to execute, already has FDA breakthrough device designation and many more clinical and regulatory needs cleared, they are already treating patients in the US as part of the FDA IDE they have for multiple tumor types, the only thing lacking is awareness making it a under the radar play - with major catalysts coming as soon as this year (PMDA approval in Japan, GBM patient, Commercialization efforts, Strategic partnership deals…)

Temporary-Alarm-744

I mean how many fathers don’t get snipe by the IDE is it really the father part or being 31 that matters?

Pristine_Hurry_4693

I’ve already answered a different comment, so not to repeat I’ll try to add value and just say the stock already has: - FDA breakthrough device designation - FDA TAP program inclusion - FDA MDSAP certification - FDA IDE’s for several cancers - FDA trials (multiple) at phase 2 and 3 - Financial runway beyond commercialization - 2 manufacturing factories built and a 3rd and largest being built in the US - 100% tumor response rate in early FDA trials - Could treat high unmet needs cancers like Pancreatic, Lungs, Brain, Breast, etc… - Activates immune system response - 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, etc…) - Patents, IP and more… Some upcoming catalysts: They treated a Pancreatic Cancer patient initiating their IMPACT study, are approved to do the same for GBM, and are expecting PMDA approval in Japan this calendar year. Still one of the most under the radar and therefore undervalued plays in a multi hundred billion dollar life saving market.

Pristine_Hurry_4693

My pleasure, you should know they already have: - FDA breakthrough device designation - FDA TAP program inclusion - FDA MDSAP certification - FDA IDE’s for several cancers - FDA trials (multiple) at phase 2 and 3 - Financial runway beyond commercialization - 2 manufacturing factories built and a 3rd and largest being built in the US - 100% tumor response rate in early FDA trials - Could treat high unmet needs cancers like Pancreatic, Lungs, Brain, Breast, etc… - Activates immune system response - 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, etc…) - Patents, IP and more… Along with the expected PMDA approval and other clinical results Best of luck!

Pristine_Hurry_4693

My favorite pick is DRTS. The stock already has: - FDA breakthrough device designation - FDA TAP program inclusion - FDA MDSAP certification - FDA IDE’s for several cancers - FDA trials (multiple) at phase 2 and 3 - Financial runway beyond commercialization - 2 manufacturing factories built and a 3rd and largest being built in the US - 100% tumor response rate in early FDA trials - Could treat high unmet needs cancers like Pancreatic, Lungs, Brain, Breast, etc… - Activates immune system response - 50+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, etc…) - Patents, IP and more… This week they successfully initiated the IMPACT study by treating the first Pancreatic Cancer patient in the US, after successfully completing their trials with over 40 Pancreatic Cancer patients in Canada. Furthermore they are expecting PMDA approval in Japan this calendar year. One of the most undervalued plays in a multi hundred billion dollar life saving market.

greenpride32

The AI infused IDE's are all just forks from VS Code and using some other company's frontier models. More or less they've created what boils down to an AI plug-in masqueraded to look like they built a full product. VS Code already does the same with Copilot. How much business worth can this product have which has little if any IP? So capital markets will prop this up to the tune of billions maybe tens of billions. Some unsuspsecting investor says look an "AI" play, I better buy it in case it blows up like everything else "AI". The fact that GOOGL poached the talent from Winsurf just shows where the value is, in the employees and talent who can build a full stack proprietary soution that has value. If the "tool" Winsurf has is so valuable, wouldn't have GOOGL tried to just purchase it all?

derprondo

Bro you don’t even copy and paste anymore, the Cursor IDE is fully integrated to do everything right in the IDE. And I am like Rain Man now btw.

DevOpsMakesMeDrink

I’m aware of all this. I have said before it is like a dangerous junior. But you can keep it on task and have it summarize documentation on things you are working on locally right in your IDE. You can ask it to look at configurations of things like live resources in a kubernetes clusters or have it recommend best practices and look for things not following them. The result is, in the right context and situation, the engineer is not wasting time doing things that are not pushing forward things. Less time researching and learning. Sometimes they are even able to recognize misconfigured services when troubleshooting. So right now, it’s very useful in a very limited context. In however many years with everyone doing these actions I expect it will become better and better. There isn’t a way I can see to fix the lack of context AI has. But I think it will get better at not hallucinating and being able to generate and even manage (look up operators) infrastructure / services at acceptable quality. And on the way it will get better and better at doing the small things so engineers can focus on the thing they are building.

MudHot8257

>Protest. I have. >Disrupt the system. In what sense, join ICE and drag my feet? >Call your local politician and ask questions about what is happening. My local politicians in California are just as neutered as the rest of us constituents. You wouldn’t know that since you’re speaking from the sidelines, you jackass. >Rauwe questions about your political system where money can buy politicians. No idea what you meant by this but presumably you’re saying be a vocal advocate against political lobbyism. I’ve had dozens of talks about citizens united and the dangers of allowing super PACs to curry political favor in exchange for money. >Don’t buy from people like Bezos and Musk. Do you understand how deeply entwined these multi multi billionaires are in our economy? It’s not as simple as: “Cancel your prime subscription and Bezos will go broke”. Here’s an AI slop list of a whole slew of companies that are Amazon subsidiaries. Bookpages Telebook IMDb Junglee PlanetAll LiveBid.com Accept.com Alexa Internet e‑Niche Incorporated Convergence Corporation Tool Crib of the North Back to Basics Toys Leep Technology Inc. MindCorps Incorporated Egghead Software OurHouse.com Joyo.com BookSurge (now CreateSpace) Mobipocket CustomFlix smallparts.com Shopbop TextPayMe Digital Photography Review (DPReview) Brilliance Audio Withoutabox Audible Fabric.com AbeBooks Shelfari Reflexive Entertainment Box Office Mojo Lexcycle SnapTell Zappos Touchco Woot Amie Street (Songza) BuyVIP Quidsi (Diapers.com & Soap.com) Toby Press LoveFilm The Book Depository Pushbutton Yap (speech recognition) Double Helix Games Teachstreet Kiva Systems (now Amazon Robotics) Evi Avalon Books UpNext IVONA Software Liquavista TenMarks Education, Inc. ComiXology Amiato Twitch Interactive Rooftop Media GoodGame Annapurna Labs 2lemetry Shoefitr ClusterK AppThwack Elemental Technologies Safaba Translation Systems Biba Systems Orbeus Colis Privé NICE Emvantage Payments Cloud9 IDE Curse, Inc. Westland Partpic harvest.ai Thinkbox Software Do.com Whole Foods Market Souq.com Graphiq GameSparks Wing.ae Body Labs Goo Technologies (Sumerian) Dispatch (Amazon Scout) Blink Home Sqrrl Ring PillPack Tapzo CloudEndure TSO Logic Eero Canvas Technology Sizmek Ad Server & Dynamic Creative Optimization Bebo E8 Storage IGDB INLT Zoox Wondery Umbra 3D Metro‑Goldwyn‑Mayer (MGM Holdings) Art19 Wickr Veeqo Spirit.ai Fig MX Player One Medical Additional Amazon-Owned Brands, Divisions & Services A9.com Shopbop Prime Prime Now Amazon Appstore Amazon Cash Amazon Digital Software & Video Games Amazon Marketplace Amazon Pay Kindle Store 1‑Click Amazon Fresh Amazon Go Treasure Truck Alexa Amazon Fire Fire TV Kindle Amazon Halo Amazon Luna Astro Kuiper Systems (Project Kuiper) Whole Foods Market (duplicate of 79) PillPack (duplicate of 90) Amazon Home Services Neighbors App Amazon Web Services (AWS) Mechanical Turk AWS Services (Aurora, Glacier, SageMaker, Lambda, S3, EC2, etc.) Amazon Drive Body Labs (duplicate of 84) Maybe by some miracle you haven’t used a single one of these companies’ products, go ahead and look up your top 10 favorite websites and see how many are hosted through AWS. Why don’t you come over here and fight on the front lines with the people you’re disparaging, rather than kicking people that are currently experiencing it? If you lived here you’d be doing the same exact thing, if not even less advocacy. It’s easy to critique when you’re watching from the sidelines, it’s harder when you have to actually face consequences for your actions.

BicyclePurple

RDGL! Keep it on your radar. Awaiting IDE approval by August 15th.

Key-Spray4403

Fda IDE approval expedited mid aug

fredditf

Amazon Q2 ’25 Earnings Highlights 🔹 Sales: $167.7 B (Est. $162.15 B) 🟢; +13% YoY 🔹 EPS: $1.68 (Est. $1.33) 🟢 🔹 Oper Income: $19.2 B (Est. $16.77 B) 🟢 🔹 AWS Net Sales: $30.87 B (Est. $30.77 B) 🟢; +17.5% YoY Q3 Guidance 🔹 Net Sales $174.0 B–$179.5 B (Est. $173.24B) 🟢 🔹 Operating Income $15.5 B–$20.5 B Segment Performance North America 🔹 Sales: $100.1 B; UP +11% YoY 🔹 Operating Income: $7.5 B International 🔹 Sales: $36.8 B; UP +16% YoY 🔹 Operating Income: $1.5 B AWS 🔹 Operating Income: $10.2 B Other Metrics 🔹 Operating Cash Flow (TTM): $121.1 B; UP +12% YoY 🔹 Free Cash Flow (TTM): $18.2 B CEO Andy Jassy Commentary 🔸 “Our conviction that AI will change every customer experience is starting to play out as we’ve expanded Alexa+ to millions of customers, continue to see our shopping agent used by many millions of customers, launched AI models like DeepFleet that optimize productivity paths for our 1M+ robots, made it much easier for software developers to write code with Kiro (our new agentic IDE), launched Strands to make it easier to build AI agents, and released Bedrock AgentCore to enable agents to be operated securely and scalably.” 🔸 “Our AI progress across the board continues to improve our customer experiences, speed of innovation, operational efficiency, and business growth, and I’m excited for what lies ahead.”

MAGS0330

Hold for a while… should get a nice pop after 8/14 when the IDE IS accepted… will also rise nicely when progress from US clinical trials are posted

danfay222

As someone who works at Meta, I promise you they are not in “panic mode” on AI. The internal AI assistants and coding models are genuinely crazy, I don’t think a public version of any of them has been released (and I’m not sure it will be) but we genuinely have tools built into our IDE where I can just describe what I want and maybe link a design doc and it will do 90% of the work for me. There’s so many products currently in the works that don’t have industry equivalents, they’re not struggling their just piling on investments

MAGS0330

RDGL… cancer killing therapy, injectable gel that hardens in the tumor, destroying it from the inside out while leaving surrounding tissue undamaged. They just submitted their IDE to the FDA on 7/14, expect approval by 8/14… clinical trials to be done in the US with the most reputable cancer research institute in the world (Mayo Clinic). YOLO everything and become RICH!!!!

BicyclePurple

Hi! I just want to remind people to keep $RDGL on your radar. We will find out if they get IDE approval in August.

MAGS0330

Smart man. The IDE decision should be made by 8/15/25. I can’t imagine they would have submitted it without a very high degree of confidence that it will be approved. The pop should come after approval but i also think there are much higher long term gains in store once they start conducting the U.S. trials and positive data comes out

Pristine_Hurry_4693

Who - a company with a revolutionary cancer treatment Why - they could potentially save millions of lives and by doing so make you millions of dollars How - they have 100% tumor response rate in early FDA trials, their treatment is effective against all solid tumors including high unmet needs like pancreatic cancer, lung cancer, GBM, breast cancer and many more (dozens were tested and all responded, currently active in 50+ clinical sites worldwide including the US, Canada, France, Italy, Germany, UK, Russia and more). They have the financial runway to get to commercialization. They have manufacturing facilities. They have FDA breakthrough device designation. They have FDA TAP program inclusion. They have FDA MDSAP certification. They have FDA IDE’s and have multiple trials going on including phase 2 and 3 already. The treatment is a one time under an hour procedure, is lethal to the cancer cells while sparing healthy tissue and little to no side effects.

MAGS0330

Honestly, with the size of the Oncology market today, and the population of patient candidates that are not ideal for surgery, I think RDGL is well positioned to capture a large underserved market. There have been many numbers thrown around, but if they get their IDE and publish successful data from US Clinical trials I think it’s not crazy for this stock to breach $3.00 easy

throwawayainteasy

My work rolled out Copilot Chat. It can't tell if it's helpful or not because it crashes every time I start using it for anything intensive. Also annoying that it has some kind of hidden formatting/characters so anytime I try to use to to help with any kind of coding/scripting, I can't just copy and paste it's output into my IDE. Anything that's indented throws and error. I have re-do all the indents. Combined, that means even though it's more of a PITA to use from our computer systems and I have to be paranoid about not exposing propriety stuff, I still use the "more limited" free version of ChatGPT instead.

WhatWeMissed

The name was reused. If you thought cursor.ai was worth anything, AWS just added at least that much value with this release. Agentic AI in an IDE that interfaces smoothly with all AWS stack is pure gold.

MAGS0330

I’d grab as much as you can. High likelihood that this IDE will be successful. We should know by AUG 15. If it is, the company becomes a big buy out target, and even if they don’t want to sell— interest from institutional investors should be a big driver to aid in handsome returns

bigginfishnchips

RDGL just submitted for IDE approval boys could be a runner

YugiohXYZ

How I almost lost money to a crypto scam: Well, "almost" is pushing it, because even as regarded as I am, I am not regarded enough to run random code on the Internet. https://m.youtube.com/watch?v=QgdzH4pVvb8 Scammer in this video provides code to execute a smart contract on Remix IDE in the Solidity language. He claims the code runs a bot that snipes new tokens--theoretically finds newly listed tokens, buys them before anyone else does, then sells them just as quickly to make a profit. Sounds too good to be true and it is. If you study the code, what it actually does is funnel the fund in your wallet into his wallet. The code tries to hide the receiver wallet address behind several layers of convoluted code. It is an interesting adventure. I've messed with Solidity and smart contracts in college, so I have a spidey sense for what is possible with smart contracts and this seemed too scammy. I'll explain how my spidey sense was tingled if anyone is interested.

Pristine_Hurry_4693

My best play is $DRTS. Usually the bigger the reward so it the risk, therefore many will miss real gains even when they hit. This stock is in a once in a lifetime position imho. With a market cap of only ~250M, the company has 90M+ cash, three factories, patented tech, FDA breakthrough device designation, FDA TAP program, FDA IDE’s, MDSAP certification and much more. One could argue the stock is fundamentally worth today more than the 3$ it’s trading at (even if no further approvals are granted). They have many FDA approved clinical trials going on, some in phase 2 and 3 already. They also past all the PMDA appliances and are expected approval in Japan this quarter. Their product is a new cancer treatment, with early clinical results showing 100% tumor response. The treatment (Alpha DaRT) can shrink tumors and make them disappear even in unmet needs cases. The treatment also showed a systemic immune response. I’d love to share more all about it if anyone would like to hear. The reason it isn’t trading around 10$ (already now, and could go much higher of course with the PMDA expected approval and then FDA and US commercialization in H1 2026) is because it has 0 PR and 0 retail exposure.

civildisobedient

> they have sufficient context I'm curious if they really do, though. My IDE of choice is IntelliJ which has a Co-Pilot plugin, but as far as I'm aware it's only able to use a small portion of your codebase (maybe just what's open in tabs?) - it's not introspecting libraries, decompiling code or pulling source code from Github to add to its context. I believe Cursor at least has complete local visibility but I'm not sure how deep it's looking within dependencies, if at all. Most of the tutorials I've seen talk about converting Github repos to markdown and then adding it to the context. Seems like something that could be... automated?

Pristine_Hurry_4693

Love the breakdown, thanks for sharing! I just answered your former comment and seeing this now. Worth noting $DRTS already: - Received FDA Breakthrough Device Designation - Got accepted into the FDA's Total Product Life Cycle Advisory Program (TAP) - Achieved MDSAP (Medical Device Single Audit Program) certification - Received FDA approval for an Investigational Device Exemption (IDE) - Is expecting PMDA approval in Japan this quarter - Is in phase 3 of FDA approved trials and has many more trials in other phases

cahe4ek555

They are submitting the IDE on or before July 14th [https://vivosinc.com/ide-submission](https://vivosinc.com/ide-submission)

AluminiumCaffeine

Anthropic is blocking windsurf IDE from using their models now that OpenAI is buying them out, all kinds of fun squabbling

MyOtherActGotBanned

Claude inside Cursor IDE is how I write 90% of my code

Cameron12221

$RDGL biotech/FDA play. Applying for IDE to start human trials. Company committed to applying within the next 50ish days I think it is now. I'll share a quick write up I did on another post. Like any early stage biotech/FDA play, high risk high reward so becareful. Vivos Inc (formally known as Radiogel) RDGL - OTCQB Biotech, kind of FDA play They have a patented treatment process where they inject Y90 into a tumor using a hydrogel mix with a small gauge needle in a grid pattern. Basically the gel is more of a liquid and after it's injected, it warms up to the body temperature and becomes more a gel than a liquid. Once it gets up to the body temperature, it holds the Y90 in place within the tumor. The Y90 gives off high doses of radiation, but the radiation only travels a short distance. Y90 is already a well studied isotope that is used in many medical uses so they know a lot about it. You can basically have your children on your lap even after being injected due to the short distance the radiation travels unlike other isotopes. Due to the short distance of the radiation travel, they can inject it and basically only give high doses of radiation from within the tumor or any area they want to be effected. Their moto is basically "precision". With Y90 half life of roughly 2.5 days, after 10 days the tumor receives almost the entire dose of radiation. After about 3 months there's a natural body cycle that will remove the dead tumor and the hydrogel. At this point the Y90 is long gone. The cool thing is that they've been treating animals with this for years. Matter of fact, we had a horse treated with it when it had a tumor on it's tail. It was a same day treatment where the animal can go home the same day. They started using it at state universities, but now have expanded into private clinics. This year they are focusing on expanding to more clinics. I think they are expecting to be in over 20 by the end of the year. They also are being used at Johns Hopkins at their animal hospital. Their animal division is called Isopet. It will be a little while before Isopet becomes profitable as they start to expand and gain market share, but the real money will be in their human division, Radiogel. They are actively working with the FDA following all their requirements and requests to build a IDE submission (to start human trials) that will be bullet proof. They even used a special program from the FDA called the Early Feasibility Study (EFS) to basically have the FDA walk you through every thing they want and have many meetings with them. Shortly after the EFS, the company was granted the Break Through Device Designation (BDD). The BDD is basically the FDA saying you meet the requirements of having a product or treatment that is safer, more effective, and likely to help people with life threatening issues. The BDD also can speed up human trials if approved because they want to get the life saving treatment to market ASAP. Another use for this is to kill dirty margin. Once a doctor cuts out cancer, it's hard to get all the cancer cells. They have used this to give radiation to the area of where the cancer was removed and has successfully reduced the chance of it coming back. The doctor doesn't want to cut out more than they have to. Doctors from the Mayo Clinic actually approached the company about getting involved to get this to market as they saw massive potential in this for so many cancers and other non cancer treatments. The Mayo Clinic doesn't allow their doctors to work directly for for-profit companies, but the Mayo Clinic gave special permission to their doctors to work with this company and help consult them. Now the Mayo Clinic has officially agreed to perform the human trials once they receive the IDE from the FDA. A top oncologist from India reached out to the company and asked them to bring this to his country. While they wait for the approval from the FDA, they are actively doing human trials in India as I type this. So far they have had massive success and are expanding the trail from their original indication of thyroid cancer in 5 people to 50 more patients with cancer anywhere in the body. To sum this up, this company has made a cancer treatment that can treat cancer basically anywhere in the body, including sensitive areas such as the brain and spine or anywhere in the body. They are currently making more uses and products for different situations. The animal treatment is starting to gain traction. They are in the process of going international already. This is a long term investment in my eyes, but if you have time, this could be one of those companies that everyone wishes they had got into for pennies and not $10+. I want to be very clear, this is not a cure for cancer. It's just another tool in the doctor's toolbox. Hopefully a very effective one that will make a difference for many. It may help slow down the spreading of the cancer, but it's treatment is made for cancer that hasn't spread such as a solid tumor. I think they could use this to attack the tumors and use chemo for the spreading aspect.

tollbearer

openAi has over 20 million paid subscribers as of last count, and it was growing at a rate that puts it on 100 million by the end of the year. That's utterly insane for a service barely 2 years old. Obviously its going to be primarily white collar workers. But theres increasing uses for blue collar workers. I was able to use it the other day to diagnose a problem with my furnace that my hvac guy could not solve. He wanted to replace the whole thing, turned out it was a fault in a simple $100 part. chatgpt guided me through the diagnostic process and even gave me links to buy the part. The guy even fitted it for free, as an apology for missing the problem. I'm sure blue collar will find many uses over time. But at the moment, it really is white collar stuff. I'm a software engineer that works for, interestingly enough, a robotics startup, and it's a core part of my workflow. Massively speeds up knowledge acquisition, helps refresh my maths, physics, knowledge of spcific systems, languages, libraries, that I've gotten rusty in. Helps me research things with deep research, helps me rapidly find the links and information I'm looking for, helps me understand other disciplines I'm working with, helps review things for gaps in my knolwedge, or mistakes in my approach. Helps with simple things like reminding me of a lnaguage feautre or tool, and IDE shortcut or feature. Just so many things... Helps bring new devs up to speed. Instead of creating or compiling reading materials and wasting time mentoring directly, I can say go ask Ai to teach you these specific things, or guide you how to do this specific process. And then theres daily life. So many uses, it's uncountable. The furnace thing. But then there is researching stuff, finding products, learning things, searching the internet way faster and getting compiled lists of everything I'm looking for instead of stumbling through google myself. Having fun, generating images, sometimes just having a hilarious chat about something, getting it to do funny accents or roleplay. Checking facts when discussing something with friends. Helping write emails and solve problems in my life, keeping me on task. I use it so much now, and so do others I know who have realized its capabilities. It's still limited for many things, but also has many uses. Don't know about your experience, but it is improving so rapidly, if you tried even just a previous model, it's a different beast. Even just its ability to search the internet and CoT make a huge difference. Also, if you treat it will do everything, it will get lost. You need to think of it like a consultant, where you are bringing them in to help you finish a job you have limited domain knolwedge in. Work through problems, understand it is, in many ways dumb, and you need to keep it on track. I once worked with a brilliant graphic designer, in that they knew every aspect of every tool and could CRANK out stuff faster than any I've ever worked with, but they, ironically, had zero design sense, and would for some reason, go off on tangents that apparently had nothing to do with the brief. I had to keep them on a very short leash, over expplain everything, check their work. You have to think of it like that. If you know what you want, it can be a very poweful tool. It knows everything. Knows all the tools, all the tricks, all the knowledge. It's just a little dumb about applying it. If you're trying to get it to do something other than give you knowledge, you have to fill that role. It's a powerful tool in that scenario. And otherwise its just super useful as a very fast way of looking up knowledge and summarizing or searching for information you might otherwise have spent much more time finding.

BurgerFoundation

I feel this will bring down the market in the short short term. Maybe catch an over reaction by the market. IDE be careful with shorts and puts.

MAGS0330

Do yourself a MASSIVE favor and seriously look into $RDGL. They should be announcing phase II clinical trial results from the trial they are conducting in India within the next 30-45 days. In addition, they are working with the US FDA to submit their IDE to begin human trials in the U.S. with the Mayo Clinic. The therapy they’ve developed is called ‘RadioGel’ and it destroy cancer without damming surrounding tissue. This will offer oncologists a massively important option for those patients not ideal for surgery or Chemo. Great time to get in. Could be life changing money. Do your own DD

badmascompany

Google with slew of products and a monster in search space, is best suited for a practical integration of AI across verticals, Microsoft can be another, but given there corporate like structure I would place my bet on Google. Be it code generation, coding agents, platforms or IDE, ads, seo, search, browser based at device local models, automated cars etc, you name it and they have it.

Impressive_Date_560

As someone who works in engineering consulting and works closely with many different businesses of all sizes, I have yet to see any company use AI in a meaningful way. The software departments are the closest. But our 1 year study of AI productivity gains yielded poor results and the program was scrapped for that reason. All the estimates the various disciplines gave for how much money AI would save ended up being massively overstated. These were people who put their reputation on the line and said they were sure it would save a ton of cash. They said this to the executive management and then failed to deliver. They wanted it to work but couldn't get it to. It turns put when you're doing work beyond entry level engineering it's just not that useful. It's about as useful as more complex IDEs were a couple of decades ago. Which is to say it is useful but not as crazy as people want to believe. I've only seen it being used in smaller companies and even their the results are mixed. One guy who was a full time employee of the customer was clearly using it and his output was trash and he quit before he was about to get fired. The bigger companies don't seem to want to touch it. It's just not accurate enough. 95% accuracy might be fine when cooking a cheeseburger or doing some small biz proto work but real engineering won't accept that. And so if a human had to go in and catch thr 5% of mistakes then it's probably cheaper to have them do the whole thing.  I have github copilot and the paid version of chatgpt and I get my money's worth from it. I use it every single day. But it's useful like a complex IDE is useful. It's marginal gains once you put the work in to really know how to leverage what it's good at and what it's not. Lots of people just won't accept it's nit great at everything.

MAGS0330

Dude, you need to get RDGL on this list like NOW. They have a highly effective cancer killing treatment and have successful phase 2 trials going on in India now, and are close to submitting their IDE with the FDA to begin trials in the U.S.

suzisatsuma

I'm a ML/AI engineer - have worked in big tech for decades. uh believe it. The agentic ai stuff is actually pretty good for a lot of the more tedious code writing. It's getting dramatically better. (there is all the incentive) There's vast amounts of boilerplate / refactoring / maintenance / and testing shit. It's not like it's off by its self. I used a lot of agentic ai integration in my IDE. They're pretty damn effective for writing code for the shit I find tedious. It's code generated at the prompt and validation of engineers tho - so making individual devs more productive.

drulingtoad

Im thinking they include auto complete. I think before AI 20% of my code was generated by the IDE. I like long descriptive variable names and generally only type in the first few letters then let auto complete write the full variable names.

Digital-Dumpsterfire

Use Interactive Brokers + TradingView or Questrade’s IQ Edge if you want built-in IDE vibes without the headache. Just remember - custom indicators won’t save you from YOLO losses

Swiftzor

I’m not even talking purely about the stock market. What happens when say a massive company like Microsoft pushes a bug with AI generated code no one catches that causes something like one drive to no longer sync? Or Amazon deploys code written by AI that causes their payment processors to charge customers the wrong amount of tax? These aren’t just hypotheticals, we’re seeing AI powered tools already cause issues like this. Last week an AI enhanced IDE signed out uses from their IDEs if they had it on more than one computer, then their customer support said that is intended functionality. Turns out the customer support was an AI chatbot and hallucinated the new policy. This is a company going through a new round of funding being valued at $10B.

Fritzkreig

[Who want to live forever?](https://www.youtube.com/watch?v=_Jtpf8N5IDE)

Least-Feeling-9307

RDGL very close to submitting for IDE. Currently conducting human trials in India. 

MAGS0330

RDGL— All the way I've invested heavily in RDGL (Vivos Inc.) because I believe their RadioGel therapy has the potential to be a game-changer in cancer treatment. This targeted radiation approach, designed to minimize damage to healthy tissue, could offer significant advantages over traditional methods. The recent BDD designation from the FDA, the positive initial trial results in India, and their partnerships with Mayo Clinic and Johns Hopkins are all strong indicators of the therapy's potential. Of course, I understand the risks involved with OTC investments, but I believe the potential reward justifies it. The IDE process with the FDA is progressing quickly and I'm extremely optimistic about their long-term success. This therapy could literally change the way cancer is treated. It’s already been proven effective in animals. Check out their website and do your own DD— but I feel like this one is a HUGE winner in the next 12 months

Paul_Robert_

Looks like an IDE from inteliJ, probably PyCharm.

McNoxey

I fundamentally disagree with you. You’re simplifying the “under the hood” component significantly. I will take back what I said about aider, because honestly I actually prefer that it is significantly less autonomous. But cline, roo, windsurf and cursor with intentional MCP usage is definitely agentic. I do agree that these tools are overhyped, but I’m not discussing the tools in their standard out-of-the-box state. I don’t know how you could say that an LLM inside an IDE that has a specific purpose (Architect, Designer, Coder) with access to different sets of tools (file read write, GitHub tools, notion tooling, database management/read capabilities) is not an agent. They’re not fully autonomous, but to say they’re not agents feels like an incredibly rigid definition.

w33bwhacker

No, they’re not. I work in this space. I’m confident because I know what I’m talking about. An IDE that pulls context is a bog-standard LLM.There’s no “variety of tools” - it’s just putting the files in the context window. An “agent” has a formal definition, going back through decades of AI research. Agents operate autonomously to take complex, multi-step actions without human intervention.

McNoxey

You’re so confidently incorrect. Cursor, cline, roo, windsurf, roo code, aider. These are all agents. They have access to, and utilize a variety of tools to support my workflow. Using an in IDE LLM that calls a variety of tools to expand its context and capabilities is absolutely more than “just an llm” There obviously are simple llm implementations in an ide that can be used as just a chat, but that is not what I’m referring to.

w33bwhacker

The fact that you keep using the word "agent" inappropriately tells me that you're just bathing yourself in hype. If you're using an AI in an IDE, it isn't an "agent". It's just an LLM. Please make a note of it.

McNoxey

They're researching but they're not at the forefront of this. Here's a very high level overview of what I do and how I'm able to achieve high quality output from these models. \--- I've spent hundreds of hours trying, learning and evolving my process. I don't have a ton of time to give you a detailed response right now, but I'll give you a really quick overview. Success in AI generation comes down to three things. Your model choice. Your prompt. Your context. You manage all of these. The AI Agents attempt to solve it, but this is like asking a car to create its own gas. You're in control so you can manage this. The Model is the engine. It defines what can and can't be done. You need to learn the limits of various models, what they'er good at and what they're not good at. It's the tool you pick for the job. Secondly is your prompt. LLMs work well off repetition. Keywords. Using solid keywords that convey a lot of meaning massively improve your output. Things like defining the types you're going to use early, then referencing those types further along in your prompt. The single class name now represents an entire data structure that the LLM understands. Finally, the context. What are you trying to do? What relevant information would *you* need to solve the problem? LLMs are trained on all of the world's knowledge, but you don't need all of the world's knowledge to solve every problem. Curate what sources/information the AI needs to solve the problem and direct it to limit it's response based on that context. \--- I use it for coding, so my workflow atm is to spend time with an AI agent in my IDE (Cursor, Windsurf, Roo, Cline etc) and create my architecture plan. I have the idea in my mind of how i want to build something, and i Use AI to flush out and transcribe that idea into text. Then i refine it into a format that another AI agent can use as the instruction set for development. Finally, I pass the detailed (sometimes 500 lines) prompt to an AI agent like Aider of Claude Code and very closely watch the output. I correct it's mistakes as it goes, always directing it to run and update tests after completion. It's unbelievable. In the last 3 months I've really focussed on obtaining a fundamental working understanding of the LLMs and it has DRASTICALLY improved my abality to control thm. Shoutout to IndyDevDan - he's a phenomenal educator that imo is leading the way in this area.

McNoxey

How much time do you have? I've spent hundreds of hours trying, learning and evolving my process. I don't have a ton of time to give you a detailed response right now, but I'll give you a really quick overview. Success in AI generation comes down to three things. Your model choice. Your prompt. Your context. You manage all of these. The AI Agents attempt to solve it, but this is like asking a car to create its own gas. You're in control so you can manage this. The Model is the engine. It defines what can and can't be done. You need to learn the limits of various models, what they'er good at and what they're not good at. It's the tool you pick for the job. Secondly is your prompt. LLMs work well off repetition. Keywords. Using solid keywords that convey a lot of meaning massively improve your output. Things like defining the types you're going to use early, then referencing those types further along in your prompt. The single class name now represents an entire data structure that the LLM understands. Finally, the context. What are you trying to do? What relevant information would *you* need to solve the problem? LLMs are trained on all of the world's knowledge, but you don't need all of the world's knowledge to solve every problem. Curate what sources/information the AI needs to solve the problem and direct it to limit it's response based on that context. \--- I use it for coding, so my workflow atm is to spend time with an AI agent in my IDE (Cursor, Windsurf, Roo, Cline etc) and create my architecture plan. I have the idea in my mind of how i want to build something, and i Use AI to flush out and transcribe that idea into text. Then i refine it into a format that another AI agent can use as the instruction set for development. Finally, I pass the detailed (sometimes 500 lines) prompt to an AI agent like Aider of Claude Code and very closely watch the output. I correct it's mistakes as it goes, always directing it to run and update tests after completion. It's unbelievable. In the last 3 months I've really focussed on obtaining a fundamental working understanding of the LLMs and it has DRASTICALLY improved my abality to control thm. Shoutout to IndyDevDan - he's a phenomenal educator that imo is leading the way in this area.

Nickeless

I’ve used it for multiple big government clients and it is absolutely slow and has god awful performance. It would take ages to run basic ETL tasks all the time. Crashes for literally no reason. Throws errors that made no sense because they were abstracted away in Palantir code and not related to the actual code I wrote. That would usually be fixed by closing the program and reopening. But sometimes it would be Palantir just having a bad day or few hours. It’s pretty atrocious software for the price. Also the IDE is horrendous. It couldn’t even highlight matching parentheses, although I think they recently added VS code, so maybe the IDE is usable now.

Nickeless

The search has gotten better over the last year. But yeah you are definitely full of it. I’m a programmer and have used it for over a year and know a lot of other programmers and non-technical users. The learning curve is steep and the interface confuses everyone for awhile. I also was using it at a massive gov organization to be fair, where there were so many datasets and projects with very similar names that it became very hard to use. Also the bugs you get when trying to run pyspark code are super annoying and the IDE is god awful. You can’t even get good parentheses / syntax highlighting. You get random weird bugs that aren’t related to your actual code, but to Foundry itself. Sometimes it just doesn’t work for periods of time randomly. Sometimes it starts working again if you restart it, sometimes not. Very Small transformations can be super slow at times. There are millions of super annoying issues that come up. Far more than other environments I’ve coded and done data engineering and data science projects in. AIP is absolute trash. Overall the software is still decent and definitely improving, but it has a shitload of annoying issues and is not that user friendly and has a steep learning curve.

Quietgoer

Their microcontrollers are not as popular as they used to be. MPLAB is a bit of a pig compared to other IDE, they have some niche stuff like the dsPIC33EP but most of their lineup isnt that special. They are some of the most awkward microcontrollers to program

reefersutherland91

not an app man. It’s code. It exists in plain text. That could be dropped into any IDE and used to create software.

Optimal-Mine9149

Speaking of them, they just released an IDE, trae Which doesn't seem too bad from the reviews And there's also UI-TARS, another chinese somewhat open source answer to open ai operator, harder to setup tho

2hurd

So wait, if I use Microsoft IDE to program then it means my app has already cost billions to develop? Great! I have to tell it to the IRS that I have such costs, can I quote you?